Home › Targets › PD-1
PD-1 (10 companies · 32 programs)
Companies with an active program directed at PD-1.
- CR-001 — Non-Small Cell Lung Cancer Phase 2
- CR-001 — Hepatocellular Carcinoma Phase 1
- CR-001 — Biliary Tract Cancer Phase 1
- CR-001 — Gastric Cancer Phase 1
- CR-001 — Colorectal Cancer Phase 1
- CR-001 — Endometrial Carcinoma Phase 1
- CR-001 — Cervical Cancer Phase 1
- CR-001 — Ovarian Cancer Phase 1
- CTX-8371 — Non-Small Cell Lung Cancer Phase 1
- CTX-8371 — Triple-Negative Breast Cancer Phase 1
- CTX-8371 — Hodgkin Lymphoma Phase 1
- CTX-10726 Phase 1
- rilvegostomig — Non-Small Cell Lung Cancer Phase 3
- rilvegostomig — Gastric Cancer Phase 3
- rilvegostomig — Biliary Tract Cancer Phase 3
- rilvegostomig — Endometrial Cancer Phase 3
- ivonescimab — Non-Small Cell Lung Cancer NDA Submitted
- ivonescimab — Colorectal Cancer Phase 3
- ivonescimab — Head and Neck Squamous Cell Carcinoma Phase 3
- ivonescimab — Urothelial Carcinoma Phase 2
- MDNA11 — Solid Tumors Phase 1
- MDNA223 Preclinical
- MDNA11 — Melanoma Phase 1
- PH-762 — Cutaneous Squamous Cell Carcinoma Phase 1
- PH-762 — Melanoma Phase 1
- PH-762 — Merkel Cell Carcinoma Phase 1
- rosnilimab — Rheumatoid Arthritis Phase 2
- Jemperli — Endometrial Cancer Approved
- Bria-IMT — Metastatic Breast Cancer Phase 3
- Bria-OTS — Metastatic Breast Cancer Phase 1
- zimberelimab — Clear Cell Renal Cell Carcinoma Phase 1
- LOQTORZI — Nasopharyngeal Carcinoma Approved
